Q BioMed Inc.
QBIO
$0.00
$0.000.00%
OTC PK
| 02/28/2023 | 11/30/2022 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -52.47% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -52.47% | |||
| Cost of Revenue | -96.88% | 20.78% | |||
| Gross Profit | 96.31% | -68.41% | |||
| SG&A Expenses | -7.55% | -33.94% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -23.02% | -28.40% | |||
| Operating Income | 21.32% | 27.59% | |||
| Income Before Tax | -131.34% | 389.59% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -131.34% | 389.59% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -131.34% | 389.59% | |||
| EBIT | 21.32% | 27.59% | |||
| EBITDA | 21.80% | 28.04% | |||
| EPS Basic | -124.76% | 200.66% | |||
| Normalized Basic EPS | -120.30% | 326.97% | |||
| EPS Diluted | -125.08% | 199.34% | |||
| Normalized Diluted EPS | -120.30% | 326.97% | |||
| Average Basic Shares Outstanding | 52.30% | 59.01% | |||
| Average Diluted Shares Outstanding | 52.30% | 59.01% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||